With the initiation of this trial, Abbott has paid a $10m milestone payment to Neurocrine.
Neurocrine president and CEO Kevin Gorman said they are pleased that their collaboration has reached this important milestone with elagolix now being evaluated in a clinical setting for use in treating uterine fibroids.
"We look forward to a continued successful collaboration with Abbott," Gorman said.